Trials / Completed
CompletedNCT03574753
Lung-MAP S1400K: c-MET Positive
A Phase II Study of ABBV-399 in Patients With C-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP SUB-STUDY)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- SWOG Cancer Research Network · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
S1400K of Lung-MAP seeks to evaluate the overall response rate with ABBV-399 (Process II) in patients with c-MET positive SCCA. S1400K is a biomarker-driven study for patients with Stage IV or recurrent squamous cell lung cancer, who have c-MET positive squamous cell tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-399 | ABBV-399 (Process II), 2.7 mg/kg IV over 30 ± 10 minutes, Day 1, Every 21 days |
Timeline
- Start date
- 2018-03-16
- Primary completion
- 2019-12-21
- Completion
- 2021-07-30
- First posted
- 2018-07-02
- Last updated
- 2021-10-18
- Results posted
- 2021-06-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03574753. Inclusion in this directory is not an endorsement.